Tics and Tourette’s Disorder: What’s New?
Barbara J. Coffey, MD, MS, Professor and Chair, Department of Psychiatry and Behavioral Sciences, Division Chief, Child and Adolescent Psychiatry, Director, Tourette Association Center of Excellence, University of Miami Miller School of Medicine
Persistent tics and Tourette’s disorder, which begin in early childhood, are highly prevalent neurodevelopmental disorders, occurring in up to 1% of the US population. The vast majority of children and adolescents with Tourette’s have comorbid psychiatric disorders, including OCD, ADHD, anxiety, and mood disorders.
Friday, October 16, 2020
9:00 am – 10:30 am ESTAdd to Cal
Although many children experience attenuation of tics by mid to late adolescence, some have continued tics and many have continued comorbid symptoms which reduce quality of life. Treatment options include both behavioral and psychopharmacologic interventions, but both types of treatments can be problematic. New pharmacological options, including VMAT2 inhibitors and a D1 dopamine antagonist, have recently been tested and may add to the therapeutic armamentarium. Guidelines for evaluation and treatment of youth with tic disorders and Tourette’s disorder based on the latest research will be discussed.
1) Comprehensively evaluate children and adolescents with tics, Tourette’s disorder and psychiatric comorbid disorders
2) Interpret results of recent clinical trials in Tourette’s disorder
3) Integrate and apply updated treatment recommendations in clinical practice